A new American Joint Committee on Cancer staging system for cutaneous melanoma

Cancer

Volumn 88, Issue 6, 2000, Pages 1484-1491

  Balch, Charles M ^a,p   Buzaid, Antonio C ^b   Atkins, Michael B ^c   Cascinelli, Natale ^d   Coit, Daniel G ^e   Fleming, Irvin D ^f   Houghton Jr , Alan ^e   Kirkwood, John M ^g   Mihm, Martin F ^h   Morton, Donald L ⁱ   Reintgen, Douglas ^j   Ross, Merrick I ^k   Sober, Arthur ^h   Soong, Seng Jaw ^l   Thompson, John A ^m   Thompson, John F ⁿ   Gershenwald, Jeffrey E ^k   McMasters, Kelly M ^o  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Istituto Nazionale per lo Studio   (Italy)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Methodist Healthcare   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ John Wayne Cancer Center   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o UNIVERSITY OF LOUISVILLE   (United States)

^p JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; MELANOMA; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BIOPSY; CLINICAL TRIALS; HUMANS; INTRAOPERATIVE CARE; L-LACTATE DEHYDROGENASE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SKIN ULCER; TREATMENT OUTCOME; UNITED STATES;

EID: 17544401946     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D     Document Type: Article

References (56)

1. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42.
2. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979;86: 343-51.
3. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677-84.
4. Buttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499-506.
5. Sondergaard K. Depth of invasion and tumor thickness in primary cutaneous malignant melanoma: a study of 2012 cases. Acta Pathol Microbiol Immunol Scand A 1985;93:49-55.
6. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
7. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 1996;125:369-75.
8. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-14.
9. Corona R, Mele A, Amini M, DeRosa G, Coppola G, Piccardi P, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218-23.
10. Lock-Andersen J, Hou-Jensen K, Hansen JP, Jensen NK, Sogaard H, Andersen PK, Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1995;29:141-8.
11. Heenan PJ, Matz LR, Blackwell JB, Kelsall GR, Singh A, ten Seldam RE, et al. Interobserver variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology 1984;8:717-29.
12. Larsen TE, Little JH, Orell SB, Prade M. International pathologists congruence survey on quantitation of malignant melanoma. Pathology 1980;12:245-53.
13. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.
14. Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995;13: 2361-2368.
15. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
16. Slingluff CL Jr., Vollmer R, Seigler HF. Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol 1988;39:139-47.
17. Drepper H, Biess B, Hofherr B, Hundeiker M, Lippold A, Otto F, et al. The prognosis of patients with stage III melanoma. Cancer 1993;71:1239-46.
18. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: a multivariate analysis. Ann Surg 1991;214: 627-36.
19. Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124:746-56.
20. Kuehnl-Petzoldt C, Wiebelt H, Berger H. Prognostic groups of patients with stage I melanoma. Arch Dermatol 1983;119: 816-9.
21. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.
22. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
23. Urist MM, Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, et al. Head and neck melanoma in 534 clinical Stage I patients: a prognostic factors analysis and results of surgical treatment. Ann Surg 1984;200:769-75.
24. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45:3012-7.
25. Cascinelli N, Marubini E, Morabito A, Bufalino R. Prognostic factors for stage I melanoma of the skin: a review. Stat Med 1985;4:265-78.
26. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in Southern Sweden, 1965, 1975, and 1985. Cancer 1997;79:275-83.
27. McGovern VJ, Shaw HM, Milton GW, McCarthy WM. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982;6:399-407.
28. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987;74:1023-6.
29. Karakousis CP, Hena MA, Emrich LJ, Driscoll DL., Axillary node dissection in malignant melanoma: results and complications. Surgery 1990;108:10-7.
30. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg 1985;201:103-7.
31. Cascinelli N, Vaglini M, Nava M, Santinami M, Marolda R, Rovini D, et al. Prognosis of skin melanoma with regional node metastases (stage II). Surg Oncol 1984;25:240-7.
32. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-9.
33. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998;16:1103-11.
34. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-34.
35. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
36. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer 1997;79:2345-53.
37. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891-6.
38. Agrawal S, Yao T-J, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 1999;6:336-44.
39. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 1998;78:40-5.
40. Sirott M, Bajorin D, Wong G, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993; 72:3091-8.
41. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191-5.
42. Meyskens FL, Berdeaux DH, Parks B, Tong T, Loescher L, Moon TE. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer 1988;62:1207-14.
43. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, et al. Efficacy of lymphadenectomy and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999;6:442-9.
44. Wanebo HJ, Cooper PH, Young DV, Harpole DH, Kaiser DL. Prognostic factors in head and neck melanoma: effect of lesion location. Cancer 1988;62:831-7.
45. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 1999;85:2391-9.
46. Prade M, Sancho-Garnier H, Cesarini JP, Cochran A. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 1980;26:159-63.
47. Keefe M, Mackie RM. The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Br J Cancer 1991;64:598-602.
48. Karakousis CP, Emrich LJ, Rao U. Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer 1989;64:1432-6.
49. Day CL Jr., Lew RA, Mihm MC Jr., Harris MN, Kopf AW, Sober AJ, et al. The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med 1981; 305:1155.
50. Day CL Jr., Lew RA, Harrist TJ. Malignant melanoma prognostic factors 4: ulceration width. J Dermatol Surg Oncol 1984;10:23-4.
51. Vollmer R. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989;24:383-407.
52. Koh HK, Sober AJ, Day CL Jr., Lew RA, Kopf AW, Lamar W, et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol 1986; 4:1238-44.
53. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991;214:491-9.
54. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet 1998;351:793-6.
55. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990;125: 322-6.
56. Crowley N, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 1990;66:2522-7.